Inventiva S.A.
IVA
Rankning i aktier
#10435
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Aktiekurs
$3.40
Marknadsvärde
$803.80M
Förändring (1 dag)
-1.08%
Förändring (1 år)
-10.29%
Land
FR
Handel Inventiva S.A. (IVA)
Kategori
Healthcare
Historik för aktiesplit för Inventiva S.A. (IVA)
Aktien Inventiva S.A. (symbol: IVA) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En IVA-aktie köpt före Oct 21, 2026 motsvarar nu 0 IVA-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En IVA-aktie köpt före Oct 21, 2026 motsvarar nu 0 IVA-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
